Dataset Information

The human DEPhOsphorylation Database DEPOD: 2019 update.

ABSTRACT: The human Dephosphorylation Database (DEPOD) is a manually curated resource that harbors human phosphatases, their protein and non-protein substrates, dephosphorylation sites and the associated signaling pathways. We report here an update to DEPOD by integrating and/or linking to annotations from 69 other open access databases including disease associations, phosphorylating kinases, protein interactions, and also genome browsers. We also provide tools to visualize protein interactions, protein structures, phosphorylation networks, evolutionary conservation of proteins, dephosphorylation sites, and short linear motifs within various proteins. The updated version of DEPOD contains 254 human phosphatases, 336 protein and 83 non-protein substrates, and 1215 manually curated phosphatase-substrate relationships. In addition, we have improved the data access as all the data in DEPOD can now be easily downloaded in a user-friendly format. With multiple significant improvements, DEPOD continues serving as a key resource for research on phosphatase-kinase networks. Database URL: www.depod.org.

SUBMITTER: Damle NP

PROVIDER: S-EPMC6911163 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

The human DEPhOsphorylation Database DEPOD: 2019 update.

Damle Nikhil P NP Köhn Maja M

Database : the journal of biological databases and curation 20190101

The human Dephosphorylation Database (DEPOD) is a manually curated resource that harbors human phosphatases, their protein and non-protein substrates, dephosphorylation sites and the associated signaling pathways. We report here an update to DEPOD by integrating and/or linking to annotations from 69 other open access databases including disease associations, phosphorylating kinases, protein interactions, and also genome browsers. We also provide tools to visualize protein interactions, protein s ...[more]

PMID: 31836896

Similar Datasets

Project description:Intratumoral immunotherapies aim to trigger local and systemic immunologic responses via direct injection of immunostimulatory agents with the goal of tumor cell lysis, followed by release of tumor-derived antigens and subsequent activation of tumor-specific effector T cells. In 2019, a multitude of intratumoral immunotherapies with varied mechanisms of action, including nononcolytic viral therapies such as PV-10 and toll-like receptor 9 agonists and oncolytic viral therapies such as CAVATAK, Pexa-Vec, and HF10, have been extensively evaluated in clinical trials and demonstrated promising antitumor activity with tolerable toxicities in melanoma and other solid tumor types. Talimogene laherparepvec (T-VEC), a genetically modified herpes simplex virus type 1-based oncolytic immunotherapy, is the first oncolytic virus approved by the U.S. Food and Drug Administration for the treatment of unresectable melanoma recurrent after initial surgery. In patients with unresectable metastatic melanoma, T-VEC demonstrated a superior durable response rate (continuous complete response or partial response lasting ?6 months) over subcutaneous GM-CSF (16.3% vs. 2.1%; p < .001). Responses were seen in both injected and uninjected lesions including visceral lesions, suggesting a systemic antitumor response. When combined with immune checkpoint inhibitors, T-VEC significantly improved response rates compared with single agent; similar results were seen with combinations of checkpoint inhibitors and other intratumoral therapies such as CAVATAK, HF10, and TLR9 agonists. In this review, we highlight recent results from clinical trials of key intratumoral immunotherapies that are being evaluated in the clinic, with a focus on T-VEC in the treatment of advanced melanoma as a model for future solid tumor indications. IMPLICATIONS FOR PRACTICE: This review provides oncologists with the latest information on the development of key intratumoral immunotherapies, particularly oncolytic viruses. Currently, T-VEC is the only U.S. Food and Drug Administration (FDA)-approved oncolytic immunotherapy. This article highlights the efficacy and safety data from clinical trials of T-VEC both as monotherapy and in combination with immune checkpoint inhibitors. This review summarizes current knowledge on intratumoral therapies, a novel modality with increased utility in cancer treatment, and T-VEC, the only U.S. FDA-approved oncolytic viral therapy, for medical oncologists. This review evaluates approaches to incorporate T-VEC into daily practice to offer the possibility of response in selected melanoma patients with manageable adverse events as compared with other available immunotherapies.

Project description:Following a request from the European Commission, EFSA was asked to create and regularly update a database of host plant species of Xylella spp. In 2018, EFSA released a new Xylella spp. host plant database that was now updated with informative data extracted from 76 recent publications retrieved through an extensive literature search. This report is related to the third version of the database published in Zenodo in the EFSA Knowledge Junction community, covering articles selected from: a systematic literature review conducted up of 30 June 2019; Europhyt database up to 15 October 2019; and relevant articles identified by EFSA Horizon scanning and personal communications from experts. Some data on Xylella fastidiosa strains and geographical coordinates included in the already published database were updated or modified with the purpose of increasing the accuracy and consistency of the database itself. Thirty-seven new host plant species of X. fastidiosa, identified through the data extracted from the selected publications, have been added to the database. Those plant species were reported as naturally infected, artificially infected or infected under unspecified conditions by subsp. multiplex, pauca or unknown (i.e. not reported in the publication) subspecies of X. fastidiosa. No additional data were retrieved for Xylella taiwanensis. Six new Sequence Types (STs) have been identified in Brazil, Italy and the USA. Information on the tolerant/resistant response of plant species or varieties to X. fastidiosa infection are also reported in the database. The overall number of Xylella spp. host plants reaches now 343 plant species, 163 genera and 64 families determined with two different detection methods, till 595 plant species, 275 genera and 85 families regardless the detection method applied. The EFSA database on Xylella spp. host plants is updated regularly with the aim to provide information and scientific support to risk assessors, risk managers and researchers dealing with Xylella spp.

Dataset Information

The human DEPhOsphorylation Database DEPOD: 2019 update.

Publications

The human DEPhOsphorylation Database DEPOD: 2019 update.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets